SPY312.23+1.71 0.55%
DIA258.42+1.11 0.43%
IXIC10,207.63+53.00 0.52%

PTC Therapeutics Sees 2020 Duchenne Franchise Revenue $320M-$340M, Provides Corporate Update

- PTC-AADC MAA submitted; BLA now expected to be submitted in 2Q 2020 - - 3 clinical trials from PTC's new redox platform to begin in 2020 - - ~ $306 million preliminary unaudited 2019 total revenue - - 2020

Benzinga · -

- PTC-AADC MAA submitted; BLA now expected to be submitted in 2Q 2020 -
- 3 clinical trials from PTC's new redox platform to begin in 2020 -
- ~ $306 million preliminary unaudited 2019 total revenue -
- 2020 Duchenne franchise revenue guidance of $320-340 million -